NCT02567643

Brief Summary

This study is designed to determine outcome for patients with 5 or more central nervous system (CNS) metastatic lesions treated with stereotactic radiosurgery (SRS).

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started May 2013

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2013

Completed
11 months until next milestone

First Submitted

Initial submission to the registry

April 3, 2014

Completed
1.5 years until next milestone

First Posted

Study publicly available on registry

October 5, 2015

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2017

Completed
Last Updated

January 11, 2022

Status Verified

March 1, 2017

Enrollment Period

3.8 years

First QC Date

April 3, 2014

Last Update Submit

December 21, 2021

Conditions

Keywords

BrainCNSMetastases

Outcome Measures

Primary Outcomes (2)

  • Overall survival

    6 months

  • Distant CNS free survival (new lesions in CNS)

    6 months

Secondary Outcomes (6)

  • Quality of life (as determined by FACT-Br)

    6 months

  • Local control (For CNS, local control refers to treated lesions)

    6 months

  • Timing and need for salvage therapy (whole brain radiation or repeat whole brain radiation)

    6 months

  • Median dose to whole brain with SRS

    6 months

  • Neurocognitive testing (Montreal Cognitive Assessment)

    6 months

  • +1 more secondary outcomes

Study Arms (1)

Stereotactic Radiosurgery

EXPERIMENTAL
Radiation: Stereotactic Radiosurgery

Interventions

Also known as: Gamma Knife, Cyber Knife, SRS
Stereotactic Radiosurgery

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • CNS metastatic disease with 5 to 25 CNS mets that require treatment (note that previous SRS, WBRT, and resection for previous CNS mets is allowed. At time of protocol treatment, patient must have 5 or more new or progressing CNS mets that require treatment, this includes new lesions not before seen or progression of previous lesions.). While definition of new lesions is fairly straightforward, the definition of progression of old lesion is at the discretion of the treating team but it is recommended that progression be defined by a multidisciplinary team (radiation oncologist, neurosurgeon, neuro-radiologist). Note that treatment of tumor bed does not count as treatment of an active lesion.
  • For example,
  • Patient with 10 lesions in 2010 who had whole brain radiation and now has 2 new lesions and progression of 3 previously noted lesions would be eligible
  • Patient with 31 lesions in 2010 who had whole brain radiation and now has 26 stable lesions and progression of 5 lesions is eligible. Although the patient has more than 25 lesions the majority are stable and do not require treatment.
  • Patient with 6 brain lesions has surgical resection of one lesion is eligible. Patient will require treatment for 5 lesions. Patient can also have treatment of surgical tumor bed but this does not count towards 5 lesions required for eligibility.
  • All lesions \< 4 cm in greatest dimension
  • Able to have an MRI with contrast
  • MRI within 6 weeks (MRI for eligibility can be done without contrast but planning MRI for radiosurgery will have contrast).
  • Patients of child-bearing age must agree to contraception until radiosurgery has been completed.
  • Patients able to undergo radiosurgery. Gamma knife radiosurgery is preferred for this protocol but cyberknife can also be used at the discretion of treating physicians.
  • Karnofsky Performance Scale (KPS) 50 or better
  • Eligible primaries:
  • Lung (NSCLC)
  • Lung (SCLC) that have had previous whole brain radiation
  • Head and Neck
  • +6 more criteria

You may not qualify if:

  • Less than 5 CNS lesions (can have had previously treated lesions by either surgery or SRS, but at time of protocol SRS must have 5 or more untreated lesions).
  • More than 25 CNS lesions that require treatment (note that the patient can have had previous metastatic lesions, but at the time of enrollment cannot have more than 25 new lesions).
  • For example:
  • Patient with 12 brain lesions has whole brain radiation in 2010, on follow-up has progression of 3 lesions is not eligible since less than 5 lesions require treatment.
  • Patient with 5 brain lesions has surgical resection of one lesions, patient is not eligible since has less than 5 lesions that require treatment.
  • Ineligible primaries Lymphoma Lung (SCLC) that have not had previous whole brain radiation Primary CNS tumors Leptomeningeal disease in CNS
  • Must not have any chemotherapy or targeted therapy within 24 hours prior to SRS
  • Patients unable to have an MRI (secondary for example to metal hardware)
  • Patients unable to have MRI contrast (secondary for example to poor renal function).
  • CNS lesion \> 4 cm in any dimension
  • KPS 40 or less
  • Serious or other life threatening illness as determined by the treating physician

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MD Anderson Cancer Center at Cooper

Camden, New Jersey, 08103, United States

Location

MeSH Terms

Conditions

Neoplasm MetastasisBrain Neoplasms

Interventions

Radiosurgery

Condition Hierarchy (Ancestors)

Neoplastic ProcessesNeoplasmsPathologic ProcessesPathological Conditions, Signs and SymptomsCentral Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

RadiotherapyTherapeuticsStereotaxic TechniquesNeurosurgical ProceduresSurgical Procedures, OperativeInvestigative Techniques
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 3, 2014

First Posted

October 5, 2015

Study Start

May 1, 2013

Primary Completion

March 1, 2017

Study Completion

March 1, 2017

Last Updated

January 11, 2022

Record last verified: 2017-03

Locations